Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27 Mar 24
8-K
Other Events
22 Mar 24
8-K
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZETĀ® Product Line in U.S. and Canada
4 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
13 Nov 23
8-K
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
7 Nov 23
8-K
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
7 Sep 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
9 Aug 23
8-K
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
21 Jul 23
424B5
Prospectus supplement for primary offering
21 Jul 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
8-K
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
7 Jun 23
8-K
Regulation FD Disclosure
16 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
8 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023
10 Apr 23
8-K
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
21 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
8 Mar 23
8-K
DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
7 Mar 23
424B5
Prospectus supplement for primary offering
7 Feb 23
8-K
DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants
6 Feb 23
8-K
Results of Operations and Financial Condition
3 Feb 23
8-K
Other Events
20 Dec 22
8-K
DURECT Announces 1-for-10 Reverse Stock Split
28 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
22 Nov 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
2 Nov 22
DEFA14A
Additional proxy soliciting materials
7 Oct 22
DEF 14A
Definitive proxy
7 Oct 22
8-K
Other Events
6 Oct 22
PRE 14A
Preliminary proxy
27 Sep 22
Latest ownership filings
SC 13G
INGALLS & SNYDER LLC
27 Mar 24
SC 13G
ASEN R SCOTT
16 Feb 24
SC 13G/A
Lion Point Capital, LP
14 Feb 24
SC 13G/A
Bleichroeder LP
1 Dec 23
4
Judith J. Robertson
23 Jun 23
4
Gail J Maderis
23 Jun 23
4
PETER S GARCIA
23 Jun 23
4
Gail M Farfel
23 Jun 23
4
Terrence F Blaschke
23 Jun 23
4
MOHAMMAD AZAB
23 Jun 23
4
Change in insider ownership
15 Mar 23
4
Norman Sussman
23 Feb 23
4
Timothy M. Papp
23 Feb 23
4
Judy R Joice
23 Feb 23
4
JAMES E BROWN
23 Feb 23
SC 13G/A
Lion Point Capital, LP
14 Feb 23
SC 13G/A
Bleichroeder LP
14 Feb 23
4
Judith J. Robertson
22 Aug 22
4
Judith J. Robertson
19 Aug 22
4
Gail J Maderis
12 Aug 22
4
Gail J Maderis
11 Aug 22
SC 13G
BlackRock Inc.
8 Jul 22
4
Timothy M. Papp
5 Jul 22
3
Timothy M. Papp
5 Jul 22
4
Judith J. Robertson
17 Jun 22
4
Gail J Maderis
17 Jun 22
4
DAVE HOFFMANN
17 Jun 22
4
PETER S GARCIA
17 Jun 22
4
Gail M Farfel
17 Jun 22
4
Terrence F Blaschke
17 Jun 22
4
MOHAMMAD AZAB
17 Jun 22
4
Judith J. Robertson
27 May 22
4
MOHAMMAD AZAB
25 May 22
4
Gail M Farfel
18 May 22
4
MOHAMMAD AZAB
18 May 22
4
Gail M Farfel
13 May 22
4
Gail M Farfel
12 May 22
4
Gail M Farfel
10 May 22
3
LI JIAN
25 Mar 22
4
Judith J. Robertson
16 Mar 22